<unk>  is an anthracycline topoisomerase II inhibitor that is FDA approved for the treatment of primary breast cancer with evidence of axillary node tumor involvement. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include leukopenia, neutropenia, anemia, thrombocytopenia, amenorrhea, lethargy, mucositis, infection, conjunctivitis, alopecia, nausea, vomiting, diarrhea and rash.
Epirubicin hydrochloride
Idarubicin hydrochloride
Pirarubicin
Amrubicin
Dihydroergocristine
Valrubicin
Doxorubicin hydrochloride
Aclarubicin